Search

Your search keyword '"Dahlof, Bjorn"' showing total 131 results
Start Over Author "Dahlof, Bjorn" Language english
131 results on '"Dahlof, Bjorn"'

5. Transcranial Laser Therapy in Acute Stroke Treatment: Results of Neurothera Effectiveness and Safety Trial 3, a Phase III Clinical End Point Device Trial

Author

Hacke, Werner, Schellinger, Peter D., Albers, Gregory W., Bornstein, Natan M., Dahlof, Bjorn L., Fulton, Rachael, Kasner, Scott E., Shuaib, Ashfaq, Richieri, Steven P., Dilly, Stephen G., Zivin, Justin, Lees, Kennedy R., Broderick, Joseph, Ivanova, Anastasia, Johnston, Karen, Norrving, Bo, Alexandrov, Andrei, Brown, David, Capone, Patrick, Chiu, David, Clark, Wayne, Cochran, Jack, Deredyn, Colin, Devlin, Thomas, Hickling, William, Howell, George, Huang, David, Hussain, Shazam, Mallenbaum, Sidney, Moonis, Majaz, Nash, Marshall, Rymer, Marilyn, Taylor, Reid, Tremwel, Margaret, Buck, Brian, Perez, Julio, Gerloff, Christian, Greiwing, Bernd, Grond, Martin, Hamman, Gerhard, Haarmeiter, Thomas, Jander, Sebastian, Köhrmann, Martin, Ritter, Martin, Schneider, Dietmar, Sobesky, Jan, Steiner, Thorsten, Steinmetz, Helmuth, Veltkamp, Roland, Weimar, Christian, Gruber, Franz, Andersson, Bjorn, Welin, Lennart, Leys, Didier, Tatlisumak, Turgut, Luft, Andreas, Lyrer, Philippe, Michel, Patrik, Molina, Carlos, and Segura, Tomas

Published
2014
Full Text
View/download PDF

6. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients

Author

Jamerson, Kenneth, Weber, Michael A., Bakris, George L., Dahlof, Bjorn, Pitt, Bertram, Shi, Victor, Hester, Allen, Gupte, Jitendra, Gatlin, Marjorie, and Velazquez, Eric J.

Subjects
Hypertension -- Care and treatment, Benazepril -- Usage, Benazepril -- Health aspects, Cardiovascular diseases -- Prevention
Abstract

A study was carried out to ascertain the benefits of using a combination therapy of benazepril-amlodipine for patients with hypertension. Results revealed that the benazepril-amlodipine therapy was better than the benazepril-hydrochlorothiazide combination for reducing the incidence of cardiovascular occurrences among patients with hypertension.

Published
2008

7. Aspirin and extended-release Dipyridamole versus Clopidogrel for recurrent stroke

Author

Yusuf, Salim, Cotton, Daniel, Ounpuu, Stephanie, Lawton, William A., Palesch, Yuko, Martin, Renee H., Albers, Gregory W., Bath, Philip, Bornstein, Natan, Chan, Bernard P.L., Sien-Tsong Chen, Cunha, Luis, Dahlof, Bjorn, De Keyser, Jacques, Donnan, Geoffrey A., Estol, Conrado, Gorelick, Philip, Gu, Vivian, Hermansson, Karin, Hilbrich, Lutz, Kaste, Markku, Chuanzhen Lu, Machnig, Thomas, Pais, Prem, Skvortsova, Veronika, and Roberts, Robin

Subjects
Aspirin -- Health aspects, Aspirin -- Usage, Stroke (Disease) -- Care and treatment, Dipyridamole -- Usage, Dipyridamole -- Health aspects, Clopidogrel -- Health aspects, Clopidogrel -- Usage
Abstract

A study attempts to evaluate the efficacy of Aspirin plus extended-release Dipyridamole against Clopidogrel in the treatment of recurrent stroke. Results conclude that both Aspirin plus extended-release Dipyridamole as well Clopidogrel were equally effective in treatment of recurrent stroke.

Published
2008

8. Telmisartan to prevent recurrent stroke and cardiovascular events

Author

Yusuf, Salim, Diener, Hans-Christoph, Sacco, Ralph L., Cotton, Daniel, Ounpuu, Stephanie, Lawton, William A., Palesch, Yuko, Martin, Renee H., Albers, Gregory W., Bath, Philip, Bornstein, Natan, Chan, Bernard P.L., Sien-Tsong Chen, Cunha, Luis, Dahlof, Bjorn, De Keyser, Jacques, Donnan, Geoffrey A., Estol, Conrado, Gorelick, Philip, Gu, Vivian, Hermansson, Karin, Kaste, Markku, Hilbrich, Lutz, Chuanzhen Lu, Machnig, Thomas, Pais, Prem, Roberts, Robin, Skvortsova, Veronika, Teal, Philip, Toni, Danilo, VanderMaelen, Carn, Voigt, Thor, Weber, Michael, and Byung-Woo Yoon

Subjects
Telmisartan -- Usage, Telmisartan -- Health aspects, Stroke (Disease) -- Prevention
Abstract

A study was conducted to evaluate the efficacy of Telmisartan as a form of treatment to prevent recurrent stroke and cardiovascular events. Results indicated that telmisartan therapy was not very effective in significantly reducing the rate of recurrent stroke, major cardiovascular events or diabetes.

Published
2008

9. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension

Author

Okin, Peter M.' Wachtell, Kristian, Devereux, Richard B., Harris, Katherine E., Jern, Sverker, Kjeldsen, Sverre, Julius, Stevo, Lindholm, Lars H., Nieminen, Markku S., Edelman, Jonathan M., Hille, Darcy A., and Dahlof, Bjorn

Subjects
Heart enlargement -- Prevention, Atrial fibrillation -- Risk factors, Antihypertensive drugs -- Dosage and administration, Cardiac patients -- Drug therapy
Abstract

Trials were conducted to test the hypothesis that in-treatment regression or continued absence of electrocardiographic left ventricular hypertrophy (LVH) during antihypertensive therapy is associated with a decreased incidence of atrial fibrillation, independent of blood pressure and treatment modality. It was concluded that antihypertensive therapy targeted at regression or prevention of electrocardiographic LVH may reduce the incidence of new-onset AF.

Published
2006

10. ASCOT-BPLA

Author

Fuchs, Flavio Danni, Gus, Miguel, Ribeiro, Jorge Pinto, Donzelli, Alberto, Malliani, Alberto, Goldstein, Mark R., Duerden, Martin, Dahlof, Bjorn, Sever, Peter, Poulter, Neil, and Wedel, Hans

Published
2006

11. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA)

Author

Poulter, Neil R., Wedel, Hans, Dahlof, Bjorn, Sever, Peter S., Beevers, D. Gareth, Caulfield, Mark, Kjeldsen, Sverre E., Kristinsson, Arni, McInnes, Gordon T., Mehlsen, Jesper, Nieminen, Markku, O'Brien, Eoin, Ostergren, Jan, and Pocock, Stuart

Subjects
Hypertension -- Drug therapy, Hypertension -- Complications and side effects, Cardiovascular diseases -- Drug therapy, Cardiovascular diseases -- Patient outcomes, Antihypertensive drugs -- Evaluation
Published
2005

12. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial

Author

Dahlof, Bjorn, Sever, Peter S., Poulter, Neil R., Wedel, Hans, Beevers, D. Gareth, Caulfield, Mark, Collins, Rory, Kjeldsen, Sverre E., Kristinsson Ami McInnes, Gordon T., Mehlsen, Jesper, Nieminen, Markku, O'Brien, Eoin, and Ostergen, Jan

Subjects
Hypertension -- Drug therapy, Antihypertensive drugs -- Evaluation, Antihypertensive drugs -- Dosage and administration
Published
2005

14. Prognostic significance of left ventricular mass change treatment of hypertension

Author

Devereux, Richard B., Gerdts, Eva, Nieminen, Markku S., Rokkedal, Jens, Aurup, Peter, Wachtell, Kristian, Boman, Kurt, Papademetriou, Vasilios, Harris, Katherine, and Dahlof, Bjorn

Subjects
Cardiovascular diseases -- Risk factors, Hypertension -- Complications, Hypertension -- Care and treatment, Cookery for hypertensives -- Complications, Cookery for hypertensives -- Care and treatment, Medical research, Medicine, Experimental
Abstract

Reduction of left ventricular (LV) mass during antihypertensive treatment whether modifies risk of major cardiovascular (CV) events independent of blood pressure change is determined. Increases baseline LV mass predicts CV complications of hypertension, but the relation between lower LV mass and outcome during treatment for hypertension is uncertain.

Published
2004

15. Relation of impaired left ventricular filling to systolic midwall mechanics in hypertensive patients with normal left ventricular systolic chamber function: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study

Author

Wachtell, Kristian, Papademetriou, Vasilios, Smith, Gunnar, Gerdts, Eva, Dahlof, Bjorn, Engblom, Erik, Aurigemma, Gerard P., Bella, Jonathan N., Ibsen, Hans, Rokkedal, Jens, and Devereux, Richard B.

Subjects
Hypertension -- Measurement, Hypertension -- Care and treatment, Heart enlargement -- Measurement, Diastole (Cardiac cycle) -- Measurement, Cardiac patients -- Medical examination, Health
Published
2004

16. Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study

Author

Wachtell, Kristian, Dahlof, Bjorn, Rokkedal, Jens, Papademetriou, Vasilious, Nieminen, Markku S., Smith, Gunnar, Gerdts, Eva, Boman, Kurt, Bella, Jonathan N., and Devereux, Richard B.

Subjects
Hypertension -- Drug therapy, Losartan -- Physiological aspects, Heart enlargement -- Development and progression, Cookery for hypertensives -- Drug therapy, Health
Published
2002

18. Effectiveness and Safety of Transcranial Laser Therapy for Acute Ischemic Stroke

Author

Zivin, Justin A., Albers, Gregory W., Bornstein, Natan, Chippendale, Thomas, Dahlof, Bjorn, Devlin, Thomas, Fisher, Marc, Hacke, Werner, Holt, William, Ilic, Sanja, Kasner, Scott, Lew, Robert, Nash, Marshall, Perez, Julio, Rymer, Marilyn, Schellinger, Peter, Schneider, Dietmar, Schwab, Stefan, Veltkamp, Roland, Walker, Michael, and Streeter, Jackson

Published
2009
Full Text
View/download PDF

23. Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients

Author

Okin, Peter M., Devereux, Richard B., Harris, Katherine E., Jern, Sverker, Kjeldsen, Sverre E., Julius, Stevo, Edelman, Jonathan M., and Dahlof, Bjorn

Subjects
Heart enlargement -- Complications and side effects, Heart enlargement -- Research, Heart failure -- Risk factors, Hospital care -- Causes of, Health
Abstract

Background: Reduction of electrocardiographic left ventricular hypertrophy (LVH) has been associated with decreased cardiovascular death, stroke, myocardial infarction, and atrial fibrillation. However, whether reduction of electrocardiographic LVH is associated with decreased heart failure is unclear. Objective: To examine the relation of reduction of electrocardiographic LVH to incident heart failure. Design: Multicenter cohort study derived from a randomized, controlled trial. Setting: Losartan Intervention For Endpoint reduction in hypertension study. Patients: 8479 hypertensive patients without history of heart failure who were randomly assigned to losartan or atenolol treatment. Measurements: Change in Cornell product electrocardiographic LVH between baseline and in-study electrocardiograms, examined as both a continuous variable and a dichotomous variable (above or below the median decrease of 236 mm x msec) to predict heart failure hospitalization occurring after the 6-month follow-up visit. Results: During mean follow-up of 4.7 years (SD, 1.1 years), 214 patients were hospitalized for heart failure (2.5%): 77 patients with an in-treatment decrease of 236 mm x msec or more (4.4 per 1000 patient-years) and 137 patients with a reduction less than 236 mm x msec during treatment (6.8 per 1000 patient-years). In a univariate Cox analysis in which change in Cornell product was treated as a time-varying continuous variable, decrease in Cornell product during treatment was associated with a decreased risk for new-onset heart failure, with a 24% lower risk for heart failure for every 817-mm x msec (1 SD of the mean) lower Cornell product (hazard ratio, 0.76 [95% CI, 0.72 to 0.80]). In a parallel analysis in which change in Cornell product was entered as a time-varying dichotomous variable, a greater-than-median in-treatment decrease in Cornell product (236 mm x msec) was associated with a 43% lower risk for heart failure (hazard ratio, 0.57 [CI, 0.44 to 0.76]). After adjustment for treatment, baseline risk factors for heart failure, baseline and in-treatment blood pressure, and baseline severity of electrocardiographic LVH, in-treatment decrease of Cornell product LVH in time-varying multivariate Cox models remained strongly associated with new heart failure hospitalization, with a 19% lower risk for every 817-mm x msec lower Cornell product treated as a continuous variable (hazard ratio, 0.81 [CI, 0.77 to 0.85]) or a 36% decreased rate of new heart failure in patients with an in-treatment reduction in Cornell product of 236 mm x msec or more (hazard ratio, 0.64 [CI, 0.47 to 0.89]; P < 0.001 for all comparisons). Limitations: Use of electrocardiographic LVH to select patients may have increased risk compared with unselected hypertensive patients, and use of hospitalization for heart failure as the end point will underestimate the incidence of new heart failure. Conclusion: Reduction in Cornell product electrocardiographic LVH during antihypertensive therapy is associated with fewer hospitalizations for heart failure, independent of blood pressure lowering, treatment method, and other risk factors for heart failure.

Published
2007

24. Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study

Author

Ibsen, Hans, Olsen, Michael H., Wachtell, Kristian, Borch-Johnsen, Knut, Lindholm, Lars H., Mogensen, Carl E., Dahlof, Bjorn, Snapinn, Steven M., Wan, Ying, and Lyle, Paulette A.

Subjects
Diabetes -- Research -- Care and treatment -- Prevention -- Analysis, Albuminuria -- Research -- Testing -- Analysis -- Prevention -- Care and treatment, Health, Testing, Care and treatment, Prevention, Analysis, Research
Abstract

OBJECTIVE--Our current aims were to investigate whether 1) baseline urinary albumin-to-creatinine ratio (UACR) predicted cardiovascular outcomes, 2) changes in UACR differed between treatments, 3) benefits of losartan were related to [...]

Published
2006

25. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA)

Author

Sever, Peter S., Poulter, Neil R., Dahlof, Bjorn, Wedel, Hans, Collins, Rory, Beevers, Gareth, Caulfield, Mark, Kjeldsen, Sverre E., Kristinsson, Arni, McInnes, Gordon T., Mehlsen, Jesper, Nieminen, Markku, O'Brien, Eoin, and Ostergren, Jan

Subjects
Heart attack -- Prevention -- Drug therapy -- Research, Diabetes -- Research, Type 2 diabetes -- Drug therapy -- Research -- Prevention, Health, Drug therapy, Prevention, Research, Dosage and administration
Abstract

OBJECTIVE--This study aims to establish the benefits of lowering cholesterol in diabetic patients with well-controlled hypertension and average/below-average cholesterol concentrations, but without established coronary disease. RESEARCH DESIGN AND METHODS--In the [...]

Published
2005

26. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study

Author

Wachtell, Kristian, Ibsen, Hans, Olsen, Michael H., Borch-Johansen, Knut, Lindholm, Lars H., Mogensen, Carl Erik, Dahlof, Bjorn, Devereux, Richard B., Beevers, Gareth, Faire, Ulf de, Fyhrquist, Frej, Julius, Stevo, Kjeldsen, Sverre E., Kristianson, Krister, Lederballe-Pedersen, Ole, Nieminen, Markku S., Okin, Peter M., Omvik, Per, Oparil, Suzanne, Wedel, Hans, Snapinn, Steven M., and Aurup, Peter

Subjects
Albuminuria -- Health aspects, Cookery for hypertensives -- Physiological aspects, Heart attack -- Risk factors, Hypertension -- Physiological aspects, Stroke (Disease) -- Risk factors, Health
Abstract

Background: Several studies have shown that albuminuria is associated with increased risk for fatal and nonfatal cardiovascular events, independent of conventional risk factors. The partition values for urine albumin-creatinine ratio (UACR) used to identify microalbuminuria have been based on studies that predicted risk in diabetic patients. Objective: To determine whether the relation between albuminuria and cardiovascular risk can be used to predict cardiovascular morbidity and mortality in hypertensive patients. Design: Multicenter cohort study derived from a randomized, controlled trial. Patients: 8206 patients with stage II or III hypertension randomly assigned to double-blind therapy with losartan or atenolol. Follow-up was 39 122 patient-years. Measurements: Renal glomerular permeability evaluated by UACR. Results: In nondiabetic hypertensive patients with left ventricular hypertrophy, the risk for the composite cardiovascular end point increased continuously as albuminuria increased (P < 0.001 for trend.) There was no specific threshold for increased risk. For every 10-fold increase in UACR, hazard ratios in nondiabetic patients increased as follows: composite end point, by 57% (95% CI, 40.6% to 75.0%); cardiovascular mortality, by 97.7% (CI, 66.5% to 235%); all-cause mortality, by 75.2% (CI, 54.0% to 99.4%); stroke, by 51.0% (CI, 28.8% to 76.9%); and myocardial infarction, by 45% (CI, 19.9% to 75.4%) (P < 0.001 for all comparisons). Values were similar in diabetic patients, although for myocardial infarction the trend was weaker and not significant. Conclusion: Increased UACR resulted in increasing risk for cardiovascular morbidity and mortality among hypertensive patients with left ventricular hypertrophy. We found no thresholds or plateaus. Risk increases at much lower UACR values than has been reported among diabetic patients.

Published
2003

27. Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial

Author

Devereux, Richard B., Dahlof, Bjorn, Kjeldsen, Sverre E., Julius, Stevo, Aurup, Peter, Beevers, Gareth, Edelman, Jonathan M., Faire, Ulf de, Fyhrquist, Frej, Berg, Sigrid Helle, Ibsen, Hans, Kristianson, Krister, Lederballe-Pedersen, Ole, Lindholm, Lars H., Nieminen, Markku S., Omvik, Per, Oparil, Suzanne, Snapinn, Steven, and Wedel, Hans

Subjects
Atenolol -- Evaluation, Losartan -- Evaluation, Hypertension -- Drug therapy, Cookery for hypertensives -- Drug therapy, Health
Abstract

Background: Cardiovascular morbidity and mortality are reduced by treatment with the angiotensin II AT(sub 1)-receptor antagonist losartan compared with conventional treatment with the beta-blocker atenolol in patients with hypertension and electrocardiogram-defined left ventricular hypertrophy, many of whom had known vascular disease. Objective: To determine whether losartan reduces cardiovascular event rates in lower-risk hypertensive patients without clinically evident vascular disease. Design: Subgroup analysis or a randomized trial. Setting: The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. Patients: 6886 men and women (57% women) 55 to 80 years of age (average, 66 years) with essential hypertension (sitting blood pressure, 160 to 200/95 to 115 mm Hg [average, 174/98 mm Hg]) and electrocardiogram-defined left ventricular hypertrophy who did not have clinically evident vascular disease. Intervention: Patients were randomly assigned to once-daily double-blind treatment with losartan or atenolol. Measurements: An end point committee ascertained end points (cardiovascular death, stroke, or myocardial infarction). Results: Blood pressure was reduced similarly by losartan and atenolol. The primary composite end point occurred in 282 losartan-treated patients (17.5 per 1000 patient-years) and 355 atenolol-treated patients (21.8 per 1000 patient-years; relative risk, 0.81 [95% CI, 0.69 to 0.95]; P=0.008). Cardiovascular death occurred in 103 losartan-treated patients and 132 atenolol-treated patients (relative risk, 0.80 [CI, 0.62 to 1.04]; P=0.092), stroke (nonfatal and fatal) occurred in 125 losartan-treated patients and 193 atenolol-treated patients (relative risk, 0.66 [CI, 0.53 to 0.82]; P0.2). New onset diabetes occurred less often in patients treated with losartan (n=173) than in patients treated with atenolol (n=254) (relative risk, 0.69 [CI, 0.57 to 0.84]; P

Published
2003

32. Diuretics in the LIFE study

Author

Kato, Johji, Eto, Tanenao, Dahlof, Bjorn, Devereux, Richard B., and Kjeldsen, Sverre E.

Published
2004

34. Relation of QT interval and QT dispersion to regression of echocardiographic and electrocardiographic left ventricular hypertrophy in hypertensive patients: The losartan intervention for endpoint reduction(LIFE) study

Author

Oikarinen, Lasse, Nieminen, Markku S., Toivonen, Lauri, Viitasalo, Matti, Wachtell, Kristian, Papademetriou, Vasilios, Sverker, Jern, Dahlof, Bjorn, Devereux, Richard B., and Okin, Peter M.

Subjects
Cookery for hypertensives -- Research, Hypertension -- Research, Electrocardiography -- Research, Heart enlargement -- Research, Electrocardiogram -- Research, Health
Published
2003

35. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA)

Author

Poulter, Neil R., Sever, Peter S., Dahlof, Bjorn, and Wedel, Hans

Subjects
British Hypertension Society -- Services, Diabetes -- Research, Cardiovascular diseases -- Drug therapy -- Research, Health, Drug therapy, Research, Services, Dosage and administration
Abstract

Response to Tseng We agree with current recomendations (1,2) that the use of statins should be based on absolute risk rather than lipid levels. All those with diabetes and hypertension [...]

Published
2005

36. Cardiovascular Outcomes According to Systolic Blood Pressure in Patients With and Without Diabetes: An ACCOMPLISH Substudy.

Author

Weber, Michael A., Bloch, Michael, Bakris, George L., Weir, Matthew R., Zappe, Dion H., Dahlof, Bjorn, Velazquez, Eric J., Pitt, Bertram, Basile, Jan N., Jamerson, Kenneth, and Hua, Tsushung A.

Subjects
ANTIHYPERTENSIVE agents, TYPE 2 diabetes complications, BLOOD pressure, BLOOD pressure measurement, COMBINATION drug therapy, CARDIAC contraction, HYPERTENSION, LONGITUDINAL method, MYOCARDIAL infarction, TYPE 2 diabetes, RISK assessment, STROKE, SURVIVAL, TREATMENT effectiveness, DISEASE incidence, BLIND experiment, DISEASE complications
Abstract

To evaluate the effects of achieved systolic blood pressure (SBP) during treatment on cardiovascular (CV) outcomes, the authors measured event rates of a composite primary endpoint (CV death or nonfatal myocardial infarction or stroke) at on-treatment SBPs of ≥140 mm Hg and the 10 mm Hg intervals of <140 mm Hg, <130 mm Hg, and <120 mm Hg in 6459 patients with diabetes (mean age, 67) and 4246 patients without diabetes (mean age, 69) from the Avoiding Cardiovascular Events in Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) trial. In the diabetic cohort, the primary endpoint was 49% lower (P<.001) at <140 mm Hg than at ≥140 mm Hg, and the separate components of this endpoint were also significantly reduced. Further SBP reductions did not improve outcomes, and at <120 mm Hg they were no longer different (except for stroke) from ≥140 mm Hg. In contrast, in the nondiabetic cohort, the primary endpoint event rate fell steadily (although not significantly) through the decreasing SBP categories until it was reduced by 45% (P=.0413) at <120 mm Hg. Total stroke rates for both the diabetic (-56%, P=.0120) and nondiabetic (-68%, P=.0067) cohorts were lowest at <120 mm Hg, and adverse renal events (serum creatinine increase ≥50%) were significantly lowest in the range of 130 mm Hg to 139 mm Hg for both cohorts. Diabetic patients (<140 mm Hg or <130 mm Hg) and nondiabetic patients (<120 mm Hg) may require different SBP targets for optimal CV protection, although stroke and renal considerations should also influence the selection of blood pressure targets. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

40. Influence of diabetes on efficacy of aliskiren, losartan or both on left ventricular mass regression.

Author

Vardeny, Orly, Pouleur, Anne-Catherine, Takeuchi, Madoka, Appelbaum, Evan, Verma, Anil, Prescott, Margaret, Smith, Beverly, Dahlof, Bjorn, and Solomon, Scott D

Abstract

Hypothesis/Introduction: We investigated whether diabetes modified the effectiveness of renin–angiotensin–aldosterone system (RAAS) inhibition on left ventricular hypertrophy (LVH) regression in hypertensive patients in the Aliskiren in Left Ventricular Hypertrophy (ALLAY) trial.Materials and methods: Participants (n=465) with LVH and a BMI > 25 kg/m2 were randomized to aliskiren 300mg, losartan 100mg or both daily for 36 weeks, and LVH regression was assessed by cardiac magnetic resonance imaging. Renin concentration, plasma renin activity and aldosterone were assessed in a subset of patients.Results: Patients with diabetes mellitus (DM) (n=111, 24%) were older (61±9 vs. 58±11 years, p=0.03), had higher BMI (32.2±4.2 vs. 30.7 ± 4 kg/m2, p=0.004), higher systolic blood pressure (148±14 vs. 145±14mmHg, p=0.03) and lower eGFR (79±16 vs. 84±16ml/min, p=0.03) at baseline. Combination therapy with aliskiren plus losartan was associated with greater LVH reduction than losartan alone in patients with DM (p=0.01), but not in patients without DM (p=0.91; unadjusted interaction p=0.06; adjusted p = 0.038). In a subset of 138 participants, plasma aldosterone was reduced to a greater extent in patients with DM (p-interaction = 0.004).Conclusions: Patients with DM and LVH may derive differential benefit with dual RAAS inhibition with a combination of aliskiren and losartan compared with losartan alone with respect to LVH reduction. Whether these findings will result in improved outcomes will be further explored in larger studies. [ABSTRACT FROM PUBLISHER]

Published
2012
Full Text
View/download PDF

41. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm: a multicentre randomised trial.

Author

Sever, Peter S, Dahlof, Bjorn, Poulter, Neil R, Wedel, Hans, Beevers, Gareth, Caulfield, Mark, Collins, Rory, Kjeldsen, Sverre E, Kristinsson, Arni, McInnes, Gordon T, Mehlsen, Jesper, Nieminen, Markku, O'Brien, Eoin, and Östergren, Jan

Subjects
*CORONARY heart disease prevention, *STATINS (Cardiovascular agents), *PATIENTS, *HYPERTENSION, *BLOOD cholesterol, *CLINICAL trials, *CEREBROVASCULAR disease prevention, *CARDIOVASCULAR disease prevention
Abstract

Summary: Background: The lowering of cholesterol concentrations in individuals at high risk of cardiovascular disease improves outcome. No study, however, has assessed benefits of cholesterol lowering in the primary prevention of coronary heart disease (CHD) in hypertensive patients who are not conventionally deemed dyslipidaemic. Methods: Of 19 342 hypertensive patients (aged 40-79 years with at least three other cardiovascular risk factors) randomised to one of two antihypertensive regimens in the Anglo-Scandinavian Cardiac Outcomes Trial, 10 305 with non-fasting total cholesterol concentrations 6.5 mmol/L or less were randomly assigned additional atorvastatin 10 mg or placebo. These patients formed the lipid-lowering arm of the study. We planned follow-up for an average of 5 years, the primary endpoint being non-fatal myocardial infarction and fatal CHD. Data were analysed by intention to treat. Findings: Treatment was stopped after a median follow-up of 3.3 years. By that time, 100 primary events had occurred in the atorvastatin group compared with 154 events in the placebo group (hazard ratio 0.64 [95% CI 0.50-0.83], p=0.0005). This benefit emerged in the first year of follow-up. There was no significant heterogeneity among prespecified subgroups. Fatal and non-fatal stroke (89 atorvastatin vs 121 placebo, 0.73 [0.56-0.96], p=0.024), total cardiovascular events (389 vs 486, 0.79 [0.69-0.90], p=0.0005), and total coronary events (178 vs 247, 0.71 [0.59-0.86], p=0.0005) were also significantly lowered. There were 185 deaths in the atorvastatin group and 212 in the placebo group (0.87 [0.71-1.06], p=0.16). Atorvastatin lowered total serum cholesterol by about 1.3 mmol/L compared with placebo at 12 months, and by 1.1 mmol/L after 3 years of follow-up. Interpretation: The reductions in major cardiovascular events with atorvastatin are large, given the short follow-up time. These findings may have implications for future lipid-lowering guidelines. [ABSTRACT FROM AUTHOR]

Published
2003
Full Text
View/download PDF

43. Characteristics of 9194 Patients With Left Ventricular Hypertrophy.

Author

Dahlof, Bjorn, Devereux, Richard B., Julius, Stevo, Kjeldsen, Sverre E., Beevers, Gareth, de Faire, Ulf, Fyhrquist, Frej, Hedner, Thomas, Ibsen, Hans, Kristianson, Krister, Lederballe-Pedersen, Ole, Lindholm, Lars H., Nieminen, Markku S., Omvik, Per, Oparil, Suzanne, and Wedel, Hans

Published
1998

44. Comparison of enalapril versus nifedipine to decrease left ventricular hypertrophy in systemic...

Author

Devereux, Richard B. and Dahlof, Bjorn

Subjects
*CARDIAC hypertrophy, *DRUG therapy
Abstract

Presents details on the Prospective Randomized Enalapril Study Evaluating Regression of Ventricular Enlargement or PRESERVE study. Study's aim of comparing the ability of enalapril and nifedipine in reducing left ventricular mass; Examination of past similar studies; Criteria for the comparison; Morbid events follow-up.

Published
1996
Full Text
View/download PDF

47. 1085-170 Benefits of losartan on preventing stroke in patients with isolated systolic hypertension: A LIFE substudy

Author

Kjeldsen, Sverre E, Dahlof, Bjorn, Devereux, Richard B, Julius, Stevo, Aurup, Peter, Edelman, Jonathan, Beevers, Gareth, de Faire, Ulf, Fyhrquist, Frej, Ibsen, Hans, Kristianson, Krister, Lederballe-Pedersen, Ole, Lindholm, Lars H, Nieminen, Markku S, Omvik, Per, Oparil, Suzanne, Snapinn, Steven M, Wedel, Hans, and Lyle, Paulette A

Published
2004
Full Text
View/download PDF

48. 812-4 Serum uric acid and ischemic stroke risk among hypertensive patients with left ventricular hypertrophy: The losartan intervention for endpoint reduction in hypertension (LIFE) study

Author

Kizer, Jorge R, Hoieggen, Aud, Alderman, Michael H, Kjeldsen, Sverre E, Dahlof, Bjorn, Julius, Stevo, Beevers, Gareth, de Faire, Ulf, Fyhrquist, Frej, Ibsen, Hans, Kristiansson, Krister, Lederballe-Pedersen, Ole, Lindholm, Lars H, Nieminen, Marku S, Omvik, Per, Oparil, Suzanne, Wedel, Hans, Edelman, Jonathan M, Snapinn, Steven M, and Devereux, Richard B

Published
2004
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results